109 related articles for article (PubMed ID: 17724740)
1. Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C.
Kowala-Piaskowska A; Mozer-Lisewska I; Figlerowicz M; Słuzewski W
Pharmacoepidemiol Drug Saf; 2007 Oct; 16(10):1095-103. PubMed ID: 17724740
[TBL] [Abstract][Full Text] [Related]
2. [Thyroid dysfunctions in children with chronic hepatitis C during interferon alpha-2b therapy].
Kupś-Rzepecka J; Woźniakowska-Gesicka T; Gołabek V
Przegl Lek; 2011; 68(6):311-5. PubMed ID: 22039668
[TBL] [Abstract][Full Text] [Related]
3. Transient Hypothyroidism and Autoimmune Thyroiditis in Children With Chronic Hepatitis C Treated With Pegylated-interferon-α-2b and Ribavirin.
Serranti D; Indolfi G; Nebbia G; Cananzi M; D'Antiga L; Ricci S; Stagi S; Azzari C; Resti M;
Pediatr Infect Dis J; 2018 Apr; 37(4):287-291. PubMed ID: 28953189
[TBL] [Abstract][Full Text] [Related]
4. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.
Wirth S; Pieper-Boustani H; Lang T; Ballauff A; Kullmer U; Gerner P; Wintermeyer P; Jenke A
Hepatology; 2005 May; 41(5):1013-8. PubMed ID: 15793840
[TBL] [Abstract][Full Text] [Related]
6. [Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
Pawłowska M; Palewicz E; Halota W
Przegl Epidemiol; 2006; 60(1):71-7. PubMed ID: 16758742
[TBL] [Abstract][Full Text] [Related]
7. [Effects of treatment with pegylated interferon and ribavirin in children with chronic hepatitis C].
Kowala-Piaskowska A; Figlerowicz M; Mozer-Lisewska I; Słuzewski W
Przegl Epidemiol; 2005; 59(2):491-8. PubMed ID: 16190558
[TBL] [Abstract][Full Text] [Related]
8. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
Hashimoto Y; Kanto H; Itoh M
J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
[TBL] [Abstract][Full Text] [Related]
9. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
[TBL] [Abstract][Full Text] [Related]
12. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
[TBL] [Abstract][Full Text] [Related]
14. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
15. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
[TBL] [Abstract][Full Text] [Related]
16. [Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
Porubcin S; Schréter I; Kristian P; Pellová A
Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):74-8. PubMed ID: 18756437
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic anemia during pegylated IFN-alpha2b plus ribavirin treatment for chronic hepatitis C: ribavirin is not always the culprit.
Gentile I; Viola C; Reynaud L; Borrelli F; Cerini R; Ciampi R; Piazza M; Borgia G
J Interferon Cytokine Res; 2005 May; 25(5):283-5. PubMed ID: 15871666
[TBL] [Abstract][Full Text] [Related]
18. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
[TBL] [Abstract][Full Text] [Related]
20. A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers.
d'Arondel C; Munteanu M; Moussalli J; Thibault V; Naveau S; Simon A; Messous D; Morra R; Blot C; Poynard T
J Viral Hepat; 2006 Mar; 13(3):182-9. PubMed ID: 16475994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
